GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development

13 Mar 2023
TOKYO, March 13, 2023 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment totaling approximately 260 million yen (US$1.9 million1) for the research and development of a new malaria drug. This investment will help identify multiple promising compounds in the early stages of research and development. (Appendix 1)
Malaria is an infectious parasitic disease that affects approximately 250 million people annually and was responsible for approximately 620,000 deaths in 2021. The World Health Organization(WHO)has set the target for reducing global malaria infections and deaths by at least 90% from 2015 levels by 20302 with a goal to ultimately eliminate malaria. However, recent progress in reducing annual deaths has stalled due to complications caused by the COVID-19 pandemic.
GHIT Fund will invest approximately 130 million yen (US$0.97 million1) in Shionogi & Co., Ltd (Shionogi), Nagasaki University, and Medicines for Malaria Venture (MMV) for a project to develop new antimalarial drugs, along with approximately another 130 million yen (US$X0.96million1) in Takeda Pharmaceutical Company Limited (Takeda Pharmaceutical) and MMV's synthetic research on novel antimalarial drugs.
"GHIT Fund supports the research and development of new drugs, vaccines and diagnostics to contribute to efforts to control and eradicate malaria," said Dr. Osamu Kunii, GHIT Fund CEO. "We hope that Japanese pharmaceutical companies along with research institutes will progress in the development of new drugs together with overseas partners. In particular, GHIT Fund has high expectations for the highly unique industry-academia collaboration between Shionogi and Nagasaki University aimed at developing a new antimalarial drug, a partnership based on the 'comprehensive collaboration in the field of infectious diseases centered on malaria' which was launched in February, 2019."
Also, at the same time, GHIT Fund invested approximately 15 million yen (US$0.1 million1) in Daiichi Sankyo RD Novare Co., Ltd. and the Global Alliance for TB Drug Development (TB Alliance) for a tuberculosis screening program.
As of March 13, 2023, there are 51 ongoing projects, including 25 discovery, 14 preclinical and 12 clinical trials3 in the GHIT portfolio. The total amount of investments since 2013 is 28.7 billion yen (US$210 million).
1 USD1 = JPY136.34, the approximate exchange rate on February 28, 2023.
2 WHO (World Health Organization): https://www.who.int/news-room/fact-sheets/detail/malaria
3 These awarded projects were selected and approved as new investments from a number of proposals to the RFP2022-002 for Screening Platform and Hit-to-Lead Platform, which was open for applications from July 2022 to January 2023.
The GHIT Fund is a Japan-based international public-private partnership fund (PPP) between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, the Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at neglected diseases, such as malaria, tuberculosis and neglected tropical diseases that afflict the world's vulnerable and underserved populations. The GHIT Fund mobilizes the Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases, in collaboration with global partners.
Appendix.1 Project Details
Appendix.2 Investment Overview (As of March 13, 2023)
Investment to date
Total investments 28.7 billion yen (US$210 million1)
Total invested projects 116(active projects 51 completed projects 65)
To know more about GHIT investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en
For more information, contact:
Katy Lenard at +1-301-280-5719 or [email protected]
Eriko Mugitani at +81-36441-2032 or [email protected]
SOURCE Global Health Innovative Technology (GHIT) Fund
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.